Davis Polk advised the initial purchaser in connection with a Rule 144A offering by CryoLife, Inc. of $100 million aggregate principal amount of its 4.250% convertible senior notes due 2025.
Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. CryoLife’s common stock is listed on the New York Stock Exchange under the symbol “CRY.”
The Davis Polk corporate team included partner Alan F. Denenberg, counsel Jason Bassetti and associate Sarah Kirk. Partner Po Sit provided tax advice. Partner Frank J. Azzopardi and associate Daniel P. Kearney provided intellectual property advice. Associate J. Taylor Arabian provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.